Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer

International Journal of Cancer

Volumn 136, Issue 1, 2015, Pages 204-211

  Zhang, Jian ^a,b   Wang, Zhonghua ^a,b   Hu, Xichun ^a,b   Wang, Biyun ^a,b   Wang, Leiping ^a,b   Yang, Wentao ^a,b   Liu, Yang ^b   Liu, Guangyu ^a,b   Di, Genhong ^a,b   Hu, Zhen ^a,b   Wu, Jiong ^a,b   Shao, Zhimin ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

basal like; cisplatin; gemcitabine; metastatic breast cancer; triple negative

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CISPLATIN; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CONSTIPATION; COUGHING; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC CORRELATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NAUSEA AND VOMITING; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SENSORY NEUROPATHY; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; ANALOGS AND DERIVATIVES; CARCINOMA, DUCTAL, BREAST; CHEMICALLY INDUCED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; SECONDARY; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, DUCTAL, BREAST; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEUTROPENIA; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84925283516     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28966     Document Type: Article

References (53)

1. Perou CM, Sorlie T, Eisen MB, et al., Molecular portraits of human breast tumours. Nature 2000; 406: 747-52.
2. Foulkes WD, Smith IE, Reis-Filho JS,. Triple-negative breast cancer. N Engl J Med 2010; 363: 1938-48.
3. Schneider BP, Winer EP, Foulkes WD, et al., Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 2008; 14: 8010-18.
4. Reis-Filho JS, Tutt AN,. Triple negative tumours: a critical review. Histopathology 2008; 52: 108-18.
5. Dent R, Hanna WM, Trudeau M, et al., Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 2009; 115: 423-28.
6. Dent R, Trudeau M, Pritchard KI, et al., Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-34.
7. Kassam F, Enright K, Dent R, et al., Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer 2009; 9: 29-33.
8. Perou CM,. Molecular stratification of triple-negative breast cancers. Oncologist 2011; 16 Suppl 1: 61-70.
9. Metzger-Filho O, Tutt A, de Azambuja E, et al., Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol 2012; 30: 1879-87.
10. Nielsen TO, Hsu FD, Jensen K, et al., Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-74.
11. Bertucci F, Finetti P, Cervera N, et al., How basal are triple-negative breast cancers? Int J Cancer 2008; 123: 236-40.
12. Prat A, Perou CM,. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011; 5: 5-23.
13. Atchley DP, Albarracin CT, Lopez A, et al., Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008; 26: 4282-88.
14. Gonzalez-Angulo AM, Timms KM, Liu S, et al., Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 2011; 17: 1082-89.
15. O'Shaughnessy J, Osborne C, Pippen JE, et al., Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364: 205-14.
16. O'Shaughnessy J, Schwartzberg LS, Danso MA, et al., A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 2011; 29: 1007.
17. Carey LA, Rugo HS, Marcom PK, et al., TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 2012; 30: 2615-23.
18. Baselga J, Gomez P, Greil R, et al., Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol 2013; 31: 2586-92.
19. Miles DW, Dieras V, Cortes J, et al., First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol 2013; 24: 2773-80.
20. Brufsky A, Valero V, Tiangco B, et al., Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat 2012; 133: 1067-75.
21. Ma CX, Ellis MJ, Petroni GR, et al., A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. Breast Cancer Res Treat 2013; 137: 483-92.
22. Andre F, Job B, Dessen P, et al., Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 2009; 15: 441-51.
23. Bergamaschi A, Kim YH, Wang P, et al., Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 2006; 45: 1033-40.
24. Isakoff SJ, Goss PE, Mayer EL, et al., TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response. J Clin Oncol 2011; 29: 1025.
25. ClinicalTrials.gov: Triple negative breast cancer trial (TNT). Available at: http://clinicaltrials.gov/show/NCT00532727.
26. Staudacher L, Cottu PH, Dieras V, et al., Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Ann Oncol 2011; 22: 848-56.
27. Fan Y, Xu BH, Yuan P, et al., Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Ann Oncol 2013; 24: 1219-25.
28. Bhattacharyya GS, Basu S, Agarwal V, et al., Single institute phase II study of weekly cisplatinum and metronomic dosing of Endoxan and methotrexate in second line metastatic breast cancer triplenegative. Eur J Cancer 2009; 7: 41.
29. ClinicalTrials.gov: Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Paclitaxel in Triple Negative Breast Cancer (TNBC). Available at: http://clinicaltrials.gov/show/NCT01287624.
30. Chew HK, Doroshow JH, Frankel P, et al., Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol 2009; 27: 2163-69.
31. Xu B, Jiang Z, Kim SB, et al., Biweekly gemcitabine-paclitaxel, gemcitabine-carboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. Breast Cancer 2011; 18: 203-12.
32. Nagourney RA, Link JS, Blitzer JB, et al., Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol 2000; 18: 2245-49.
33. Bergman AM, Ruiz VHV, Veerman G, et al., Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996; 2: 521-30.
34. van Moorsel CJ, Kroep JR, Pinedo HM, et al., Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors. Ann Oncol 1999; 10: 441-48.
35. Lee E, McKean-Cowdin R, Ma H, et al., Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. J Clin Oncol 2011; 29: 4373-80.
36. Comen E, Davids M, Kirchhoff T, et al., Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women. Breast Cancer Res Treat 2011; 129: 185-90.
37. Kwong A, Ng EK, Wong CL, et al., Identification of BRCA1/2 founder mutations in Southern Chinese breast cancer patients using gene sequencing and high resolution DNA melting analysis. PLoS One 2012; 7: e43994.
38. Cheang MC, Voduc D, Bajdik C, et al., Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008; 14: 1368-76.
39. Rakha EA, Elsheikh SE, Aleskandarany MA, et al., Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 2009; 15: 2302-10.
40. Carmichael J, Possinger K, Phillip P, et al., Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995; 13: 2731-36.
41. Sledge GJ, Roth BJ,. Cisplatin in the management of breast cancer. Semin Oncol 1989; 16: 110-15.
42. Erten C, Demir L, Somali I, et al., Cisplatin plus gemcitabine for treatment of breast cancer patients with brain metastases; a preferential option for triple negative patients? Asian Pac J Cancer Prev 2013; 14: 3711-17.
43. Koshy N, Quispe D, Shi R, et al., Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast 2010; 19: 246-48.
44. Arnedos M, Bihan C, Delaloge S, et al., Triple-negative breast cancer: are we making headway at least? Ther Adv Med Oncol 2012; 4: 195-210.
45. Peshkin BN, Alabek ML, Isaacs C,. BRCA1/2 mutations and triple negative breast cancers. Breast Dis 2010; 32: 25-33.
46. Lips EH, Mulder L, Hannemann J, et al., Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy. Ann Oncol 2011; 22: 870-76.
47. Lehmann BD, Bauer JA, Chen X, et al., Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121: 2750-67.
48. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
49. Hurley J, Reis IM, Rodgers SE, et al., The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients. Breast Cancer Res Treat 2013; 138: 783-94.
50. Lopez JA, Mann J, Grapski RT, et al., Etoposide and cisplatin salvage chemotherapy for small cell lung cancer. Cancer Treat Rep 1985; 69: 369-71.
51. Kim JH, Lee DH, Shin HC, et al., A phase II study with gemcitabine and split-dose cisplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2006; 54: 57-62.
52. Funai K, Takamochi K, Itaya T, et al., Feasibility study of adjuvant chemotherapy with gemcitabine and split-dose cisplatin for completely resected non-small-cell lung cancer. Lung Cancer 2010; 68: 78-83.
53. Luo Z, Chang J, Guo Y, et al., Continuous infusion of 5-FU with split-dose cisplatin: an effective treatment for advanced squamous-cell carcinoma of the head and neck. Clin Invest Med 2011; 34: E8-13.